Ensuring data integrity: Best practices and strategies in pharmaceutical industry

Abstract

Background: The objective of this article is to examine the challenges and best strategies for incorporating data integrity in the pharmaceutical industry to ensure regulatory compliance. It highlights the importance of data governance policies, secure data handling processes, and the use of the ALCOA framework for implementing Good Documentation Practices.

Evidence acquisition: Using appropriate search terms such as ‘Data Integrity', ‘Data Integrity in Pharmaceutical Industry', and ‘ALCOA principle', evidence was gathered from websites and published articles using SciFinder, Web of Science, PubMed, UGC-approved journals, and Google Scholar databases.

Results: The article emphasizes the importance of change management, independent data review methods, and modern technology such as electronic signatures and audit trails in pharmaceutical companies. It also points out the importance of data backup, recovery procedures, and ongoing improvement in maintaining data integrity and promoting responsibility.

Conclusion: The article discusses the pharmaceutical sector's procedures for ensuring data integrity throughout a product's life, promoting safe, efficient, and excellent pharmaceutical goods. It highlights the need to navigate the complex regulatory environment and emphasizes the sector's commitment to maintaining data integrity to achieve high quality standards in manufacturing and testing operations.

Keywords

Data integrity / ALCOA / Data / Good documentation practices (GDPs)

References

[1] MHRA GMP Data Integrity definitions and guidance for industry March 2015 Introduction. (n.d.).

[2] PIC/S Guidance Good Practices for Data Management and Integrity in Regulated GMP/GDP Environments.

[3] www.coursera.org/articles/what-is-data-integrity.

[4] Boritz JE . IS practitioners' views on core concepts of information integrity. Int J Account Inf Syst. 2005; 6 (4): 260- 279.

[5] Nikam NR , Patil PR , Vakhariya RR , Mohite SK , Magdum CS . Data integrity:an overview. Int J Recent Sci Res. 2020; 11 (06A): 38762- 38767.

[6] Naseem A Charoo , Khan Mansoor A , Rahman Ziyaur . Data integrity issues in pharmaceutical industry:common observations, challenges and mitigations strategies. Int J Pharm. 2023; 63: 122503.

[7] Rogers CA , Ahearn JD , Bartlett MG . Data integrity in the pharmaceutical industry:analysis of inspections and warning letters issued by the Bioresearch Monitoring Program between fiscal years 2007-2018. Ther Innovation Regul Sci. 2020; 54 (5): 1123- 1133.

[8] Kulyadi GP , Jaiswal H , Muddukrishna B . Data integrity violations: a challenge to the pharmaceutical industry. Int J Pharmaceut Qual Assur. 2020; 11 (1): 193- 195.

[9] Woollen SW . Quality Systems Compliance LLC, Durivage M. Data Integrity for the FDA Regulated Industry. Quality Systems Compliance LLC; 2019.

[10] Singh S , Punjabi N , Shah D . Importance of data integrity in pharmaceutical industry. EPRA Int J Econ Bus Manag Stud. 2023; 10 (2): 100- 106.

[11] Vignesh M , Ganesh GNK . Current status, challenges and preventive strategies to overcome data integrity issues in the pharmaceutical industry. Int J Appl Pharm. 2020; 12 (6): 19- 23.

[12] Shmmon A , Kumar A , Hafeez A . Importance of data integrity & its regulation in pharmaceutical industry. Pharma Res. 2019; 8: 306- 313.

[13] Dharnish R , Jeyaprakash MR . An approach of data integrity in pharmaceutical industries. Eur Chem Bull. 2023; 12 (1): 30- 36.

[14] www.ibm.com/blog/data-integrity-examples/.

[15] Jain SK . Strategy to avoid data integrity issues in pharmaceutical industry. Pharm Innov. 2017; 6 (2): 110- 115.

[16] O'Keeffe G . Unintentional Vs Intentional Data Integrity Mistakes[Video]. LearnGxP: Accredited Online Life Science Training Courses; 2024.

[17] Duggineni S . Data integrity and risk. Open J Optim. 2023; 12 (2): 25- 33.

[18] Pedro F , Veiga F , Mascarenhas-Melo Filipa . Impact of GAMP 5, data integrity and QbD on quality assurance in the pharmaceutical industry:how obvious is it? Drug Discov Today. 2023; 28 (11): 103759.

[19] Chavan SM , Biradar SV , Sonawane JK , et al. A review:an illustration of data integrity. Int J Res Publ Rev. 2023; 4 (5): 5620- 5629.

[20] www.zendata.dev. (n.d.). PII, PI and sensitive data:types, differences and privacy risks.

[21] Kumar K . Data integrity in pharmaceutical industry. J Analytic Pharm Res. 2016; 2 (6): 210- 211.

[22] Ingale MH , Tayade M , Patil YP , Salunkhe RR . Data integrity violations in the pharmaceutical industry and regulatory measures. Int J Pharmaceut Qual Assur. 2023; 14 (2): 416- 420.

[23] Under the spotlight. Deloitte United Kingdom. www2.deloitte.com/uk/en/pages/life-sciences-and-healthcare/articles/data-integrity-life-sciences.html.

[24] Bhadrashette MS . Overview of data integrity issues in the pharmaceutical industry. Int J Pharmaceut Sci Rev Res. 2018; 50 (2): 95- 101.

RIGHTS & PERMISSIONS

The Authors. Publishing services by Elsevier B.V. on behalf of Higher Education Press and KeAi Communications Co. Ltd.